Seattle Genetics, a leading cancer drug research center, has rolled out a new plan for for more medicines and a bigger workforce. The company has made milestone achievements since it pitched camp in Seattle with Clay Siegal at the top of its leadership. Its famous drug Adcetris has proved to be effective with many tests indicating a bright future for cancer patients in the United States.
In a bid to counteract the rising need for cancer drugs, the company will release 12 more drugs in its chain. To make this a reality, it will employ more people to enhance production. This move has cemented Seattle Genetics’ position as a leading cancer research center in the country. According to CEO Clay Siegal, the company is already at the initial stages of developing the new drugs with one of them, 33A, set for clinical trials before the end of this year. The drug is designed to treat acute leukemia. Other drugs will be used to treat breast and bladder cancer.
About Clay Siegal
Clay Siegal started his career as a research specialist in rather an amazing way. He didn’t go through the conventional system. Instead, he started as a bio-technician. He then developed a deep interest in genetics. Today, Siegal is a well-known scholar and business leader who got what it takes to lead one of the most complex companies.
Alongside other partners, he co-founded Seattle Genetics in 1998. The company had to undergo a series of financing in order to survive. One of its largest funding ever generated over $330 million. The funding was organized for both public and private financiers.
Clay Siegal also sits in several boards. He was recently appointed to the board membership of Mina Therapeutics. He also serves as a board member at Ultragenyx since 2014. Clay Siegal continues to dedicate his time and efforts to ensure Seattle Genetics becomes a leading research center for cancer drugs. He is confident that the company will make part of cancer research history. For now, his focus is on making new drugs and ensuring they work for patients all over the world.